Blood Research最新文献_第4页

Lenalidomide as a treatment for patients with AL amyloidosis and cardiac involvement. 来那度胺是治疗 AL 淀粉样变性和心脏受累患者的一种方法。

IF 2.2

Blood Research Pub Date : 2023-12-31 DOI: 10.5045/br.2023.2023194

Seo Yoon Jang, Ja Min Byun, Sung-Soo Yoon, Jin Chul Paeng, Seung-Pyo Lee, Youngil Koh

引用次数: 0

A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma. 伊布替尼治疗复发或难治套细胞淋巴瘤疗效的回顾性分析。

IF 2.2

Blood Research Pub Date : 2023-12-31 DOI: 10.5045/br.2023.2023208

Yong-Pyo Lee, Ye Ji Jung, Junhun Cho, Young Hyeh Ko, Won Seog Kim, Seok Jin Kim, Sang Eun Yoon

{"title":"A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma.","authors":"Yong-Pyo Lee, Ye Ji Jung, Junhun Cho, Young Hyeh Ko, Won Seog Kim, Seok Jin Kim, Sang Eun Yoon","doi":"10.5045/br.2023.2023208","DOIUrl":"10.5045/br.2023.2023208","url":null,"abstract":"Background: While treatment strategies for mantle cell lymphoma (MCL) have evolved, patients often experience disease progression and require additional treatment therapies. Ibrutinib presents a promising option for relapsed or refractory MCL (RR-MCL). This study investigated real-world treatment outcomes of ibrutinib in patients with RR-MCL.Methods: A single-center retrospective analysis investigated clinical characteristics and survival outcomes of patients with RR-MCL, treated with ibrutinib.Results: Forty-two patients were included, with 16 received rituximab and bendamustine, and 26 receiving anthracycline-based regimens as front-line treatment. During a median follow-up of 46.0 months, the response rate to ibrutinib was 69%, with 12 CRs and 8 partial responses. Disease progression (54.8%) and adverse events (11.9%) were the primary reasons for discontinuation. Median progression-free survival (PFS) and overall survival (OS) were approximately 16.4 and 50.1 months, respectively. Patients older than 70 years (P=0.044 and P=0.006), those with splenomegaly (P=0.022 and P=0.006), and those with a high-risk simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) (P＜0.001 and P＜0.001) exhibited siginificantly inferior PFS and OS. Notably, patients with a high-risk sMIPI relapsed earlier. Post-ibrutinib treatment yilded an OS of 12.2 months, while clinical trial participants demonstrated superior survival compared to those receiving chemotherapy alone.Conclusion: This study underscores the importance of considering patient characteristics before administering ibrutinib as salvage therapy. Early relapse was associated with poor outcomes, highlighting the need for novel therapeutic strategies.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 4","pages":"208-220"},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758639/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049501","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study. brentuximab vedotin在复发或难治性cd30阳性淋巴瘤患者中的多中心非介入性注册:CISL1803/BRAVO研究

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023206

Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang

{"title":"A multi-center and non-interventional registry of brentuximab vedotin in patients with relapsed or refractory CD30-positive lymphoma: the CISL1803/BRAVO study.","authors":"Seok Jin Kim, Young Rok Do, Ho-Sup Lee, Won-Sik Lee, Jee Hyun Kong, Jae-Yong Kwak, Hyeon-Seok Eom, Joon Ho Moon, Jun Ho Yi, Jeong-Ok Lee, Jae-Cheol Jo, Deok-Hwan Yang","doi":"10.5045/br.2023.2023206","DOIUrl":"10.5045/br.2023.2023206","url":null,"abstract":"Background: Brentuximab vedotin (BV), a potent antibody-drug conjugate, targets the CD30 antigen. In Korea, BV has been approved for the treatment of relapsed or refractory Hodgkin lymphoma (HL), anaplastic large-cell lymphoma (ALCL), and cutaneous T-cell lymphomas, including mycosis fungoides (MF). However, there are limited data reflecting real-world experiences with BV treatment for HL, ALCL, and MF.Methods: This was a multicenter, non-interventional registry study of the efficacy and safety of BV in patients with relapsed or refractory CD30-positive lymphoma (CISL1803/BRAVO). Outcomes were determined based on the occurrence of relapse or progression and overall survival after BV treatment.Results: A total of 85 patients were enrolled in this study. The median number of BV cycles was 10 (range, 2‒16) in the patients with HL. The objective response rate (ORR) of patients with HL to BV was 85.4% (41/48), comprising 27 complete responses (CRs) and 14 partial responses (PRs). The ORR of ALCL was 88% (22/25), consisting of 17 CRs and five PRs, whereas the ORR of MF was 92% (11/12). At the median follow-up of 44.6 months after BV treatment, the median post-BV progression-free survival of HL, ALCL, and MF patients was 23.6 months, 29.0 months, and 16.7 months, respectively (P=0.641). The most common side effect of BV was peripheral neuropathy; 22 patients (25.9%, 22/85) experienced peripheral neuropathy (all grades).Conclusion: The treatment outcomes of patients with relapsed or refractory CD30-positive lymphoma improved with BV treatment, and the safety profile was manageable.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"194-200"},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758628/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

T-cell large granular lymphocytic leukemia with low-grade bone marrow involvement complicated by acquired pure red cell aplasia. t细胞大颗粒淋巴细胞白血病伴低级别骨髓受累并获得性纯红细胞发育不全。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-15 DOI: 10.5045/br.2023.2023141

Bernhard Strasser, Sonja Heibl, Josef Thaler, Alexander Haushofer

引用次数: 0

Clinico-pathological features and treatment outcomes of high-grade B cell lymphoma-a tertiary cancer center experience. 高级别B细胞淋巴瘤的临床病理特征和治疗结果-三级癌症中心的经验。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023169

Anindya Mukherjee, Sujay Rainchwar, Aakanksha Singh, Rohan Halder, Pritish Chandra Patra, Rayaz Ahmed, Dinesh Bhurani, Narendra Agrawal

引用次数: 0

Successful recovery of poor graft function by administration of romiplostim in a multiple myeloma case with poor graft function following autologous stem cell transplantation. 自体干细胞移植后移植物功能差的多发性骨髓瘤患者应用罗米普罗stim成功恢复移植物功能差。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023185

Jeongmin Yim, Sung-Soo Park, Jong-Mi Lee, Jae-Ho Yoon, Hee-Je Kim, Chang-Ki Min

引用次数: 0

Ibrutinib combined with gemcitabine-vinorelbine for primary refractory non-Hodgkin lymphoma. 伊鲁替尼联合吉西他滨-长春瑞滨治疗原发性难治性非霍奇金淋巴瘤。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-15 DOI: 10.5045/br.2023.2023182

Muruvvet Seda Aydin, Esra Cengiz, Ferda Can, Simten Dagdas, Imdat Dilek, Gulsum Ozet

引用次数: 0

Recent advances in cellular immunotherapy for lymphoid malignancies. 淋巴细胞恶性肿瘤细胞免疫治疗的最新进展。

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-15 DOI: 10.5045/br.2023.2023177

Haerim Chung, Hyunsoo Cho

引用次数: 0

Correlation between red blood cell distribution width/platelet count and prognosis of newly diagnosed diffuse large B-cell lymphoma. 新诊断弥漫性大b细胞淋巴瘤红细胞分布宽度/血小板计数与预后的关系

IF 2.2

Blood Research Pub Date : 2023-12-31 Epub Date: 2023-11-30 DOI: 10.5045/br.2023.2023156

Xiaobo Liu, Yanliang Bai, Ying Liu, Weiya Li, Yabin Cui, Jinhui Xu, Xingjun Xiao, Xiaona Niu, Kai Sun

{"title":"Correlation between red blood cell distribution width/platelet count and prognosis of newly diagnosed diffuse large B-cell lymphoma.","authors":"Xiaobo Liu, Yanliang Bai, Ying Liu, Weiya Li, Yabin Cui, Jinhui Xu, Xingjun Xiao, Xiaona Niu, Kai Sun","doi":"10.5045/br.2023.2023156","DOIUrl":"10.5045/br.2023.2023156","url":null,"abstract":"Background: Red blood cell distribution width/platelet count ratio (RPR) is a reliable prognostic assessment indicator for numerous diseases. However, no studies to date have examined the relationship between RPR and the prognosis of diffuse large B-cell lymphoma (DLBCL). Therefore, this study aimed to investigate the correlation between RPR and the clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma.Methods: We retrospectively studied 143 patients with newly diagnosed DLBCL and used the median value as the RPR threshold. We also investigated the correlation of pretreatment RPR level with clinical characteristics and its impact on DLBCL prognosis.Results: Using the median value as the cut-off, patients with DLBCL were divided into a low RPR group (＜0.0549) and a high RPR group (≥0.0549). Patients in the high RPR group were older, had a later Ann Arbor stage, were prone to bone marrow invasion, and had a higher National Comprehensive Cancer Network International Prognostic Index score (P＜0.05). A survival analysis showed that progression-free survival (PFS) (P=0.003) and overall survival (OS) (P＜0.0001) were significantly shorter in the high versus low RPR group. A multifactorial Cox analysis showed that bone marrow invasion and elevated lactate dehydrogenase (LDH) were separate risk factors for PFS (P＜0.05), while an RPR ≥0.0549 and elevated LDH were separate risk factors for OS (P＜0.05).Conclusion: A high RPR (≥0.0549) in patients with newly diagnosed DLBCL is an independent risk factor for a poor prognosis.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":" ","pages":"187-193"},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758632/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138463397","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The association of pro-oxidant/antioxidant balance and blood parameters in patients with beta-thalassemia major: a cross-sectional study. 重型β-地中海贫血患者的促氧化剂/抗氧化剂平衡与血液参数的关系：一项横断面研究。

IF 2.2

Blood Research Pub Date : 2023-12-31 DOI: 10.5045/br.2023.2023174

Maryam Parvizi, Maryam Deldadeh Moghaddam, Shiva Nazari, Hami Ashraf, Maryam Kazemi Aghdam

{"title":"The association of pro-oxidant/antioxidant balance and blood parameters in patients with beta-thalassemia major: a cross-sectional study.","authors":"Maryam Parvizi, Maryam Deldadeh Moghaddam, Shiva Nazari, Hami Ashraf, Maryam Kazemi Aghdam","doi":"10.5045/br.2023.2023174","DOIUrl":"10.5045/br.2023.2023174","url":null,"abstract":"Background: Oxidative stress due to iron accumulation in patients with beta-thalassemia major (BTM) causes complications such as tissue damage and destruction. This study aimed to assess the association between the serum prooxidant/antioxidant balance (PAB) and blood parameters in patients with BTM.Methods: This cross-sectional study included 92 patients with BTM. In this study, PAB was measured using an enzyme-linked immunosorbent assay (ELISA). Serum ferritin, blood urea nitrogen (BUN), creatinine (Cr), alanine aminotransferase (ALT), aspartate aminotransferase (AST), thyroid-stimulating hormone (TSH), total cholesterol (TC), triglyceride (TG), complete blood cell count (CBC), and history of blood transfusion were recorded. The association of the blood parameters was assessed across the tertiles (T) of serum PAB (highest T vs. lowest T).Results: The results showed that high serum ferritin was directly associated with serum PAB [odds ratio (OR), 12.80; 95% confidence interval (CI), 2.98‒54.91; T3 vs. T1]. Also, direct associations were found for high TC (OR, 4.97; 95% CI, 1.42‒17.32; T3 vs. T1), high ALT (OR, 4.95; 95% CI, 1.33‒18.46; T3 vs. T1) and high TSH (OR, 3.78; 95% CI, 1.10‒13.02; T3 vs. T1).Conclusion: The findings of the present study showed that serum PAB levels were directly associated with ferritin, ALT, TC, and TSH levels. This indicates that improvements in blood parameters, especially ferritin and TSH levels, occur by ameliorating oxidative stress in patients with BTM.","PeriodicalId":46224,"journal":{"name":"Blood Research","volume":"58 4","pages":"201-207"},"PeriodicalIF":2.2,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10758633/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049527","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0